Long-Term Androgen Deprivation Plus Radiation For High Risk Prostate Cancer

Almudena Zapatero MD PhD Senior Consultant Dpt Radiation Oncology Instituto Investigación Sanitaria IIS-IP Hospital Universitario de la Princesa MadridMedicalResearch.com Interview with:
Almudena Zapatero MD PhD

Senior Consultant Dpt Radiation Oncology
Instituto Investigación Sanitaria IIS-IP
Hospital Universitario de la Princesa

Medical Research: What is the background for this study? What are the main findings?

Dr. Zapatero: There is a significant body of evidence from randomized trials showing a significant improvement in clinical outcome with the combination of androgen deprivation and conventional-dose radiotherapy (≤70 Gy) in patients with high-risk and intermediate-risk prostate cancer. However, the optimal duration the optimum duration of androgen deprivation in the setting of high-dose radiotherapy remained to be determined.

The results of our trial (DART01/05) show that 2 years of adjuvant androgen deprivation is superior to 4 months androgen deprivation when combined with plus high-dose radiotherapy  in terms of biochemical control, freedom from metastasis and overall survival, particularly in patients with high-risk prostate cancer.

Medical Research: What should clinicians and patients take away from your report?

Dr. Zapatero: That high-dose radiotherapy combined with long-term androgen ablation is an ambulatory, efficient, very effective and safe treatment for patients with high-risk prostate cancer, associated with a high rate of tumor control and a good quality of life: 2 years of adjuvant hormone therapy and high dose radiotherapy is the new standard for these patients.

Medical Research: What recommendations do you have for future research as a result of this study?

Dr. Zapatero:

First, to determine the effect of long-term androgen deprivation in patients with unfavorable intermediate-risk prostate cancer.

Second, to identify the potential relationship between the testosterone recovery following treatment and the clinical outcome, and

third, to determine the impact on bone mineral density of hormone therapy according to its duration.


High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial

Zapatero, Almudena et al.

The Lancet Oncology

DOI: http://dx.doi.org/10.1016/S1470-2045(15)70045-8

MedicalResearch.com Interview with:Almudena Zapatero MD PhD (2015). Long-Term Androgen Deprivation Plus Radiation For High Risk Prostate Cancer

[wysija_form id=”1″]


Last Updated on February 22, 2015 by Marie Benz MD FAAD